In the years since Bong Joon Ho made Oscar history with “Parasite”s best picture victory in 2020, the Korean director’s ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical ... Health leaders from around the world are marking the first ever World Parasite Awareness Day, a collective effort to raise awareness ...

a parasite that can lurk in undercooked meat and inflicts sufferers with diarrhea, vomiting, and fever. One scholar posits that the domesticated chicken’s arrival from Iran provided an ...

CAMBRIDGE, Mass., February 25, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company dedicated to developing treatments for serious diseases, has granted inducement equity awards to seven newly hired ...

Jay Backstrom; President, Chief Executive Officer, Director; Scholar Rock Holding Corp Tracey Sacco; Chief Commercial Officer; Scholar Rock Holding Corp Good morning and welcome to Scholar Rock's ...

A number of brokerages recently issued reports on SRRK. HC Wainwright increased their target price on Scholar Rock from $40.00 to $50.00 and gave the stock a “buy” rating in a report on ...

Scholar Rock (SRRK) announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial will be presented in multiple clinical presentations at the 2025 Muscular Dystrophy ...

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...